MMONARCh-1: Study of MSDC-0602K, a Modulator of the Mitochondrial Pyruvate Carrier for Outcomes in Patients With Pre Type 2 Diabetes (T2D) or T2D and NAFLD/NASH, Assessed for ImpRoved Glycemic Control and Cardiovascular Outcomes-1
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Azemiglitazone (Primary)
- Indications Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms MMONARCh
- Sponsors Cirius Therapeutics
Most Recent Events
- 08 Jul 2021 Planned End Date changed from 1 Nov 2023 to 1 Sep 2024.
- 08 Jul 2021 Planned primary completion date changed from 1 Nov 2023 to 1 Sep 2024.
- 08 Jul 2021 Planned initiation date changed from 1 Aug 2021 to 1 Jun 2022.